GALERA THERAPEUTICS INC (GRTX) Stock Price, Quote, News and Overview
NASDAQ:GRTX - Nasdaq - US36338D1081 - Common Stock - Currency: USD
GRTX Quote, Performance and Key Statistics
0.145
-0.07 (-32.59%)
The current stock price of GRTX is 0.145 USD. In the past month the price decreased by -22.04%. In the past year, price decreased by -95.51%.
GRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GRTX
Company Profile
Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 31 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. The company has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
Company Info
GALERA THERAPEUTICS INC
45 Liberty Blvd., Suite 230
Malvern PENNSYLVANIA 19355 US
CEO: J. Mel Sorensen
Employees: 31
Company Website: https://www.galeratx.com/
Phone: 16107251500
GALERA THERAPEUTICS INC / GRTX FAQ
What is the stock price of GALERA THERAPEUTICS INC today?
The current stock price of GRTX is 0.145 USD. The price decreased by -32.59% in the last trading session.
What is the ticker symbol for GALERA THERAPEUTICS INC stock?
The exchange symbol of GALERA THERAPEUTICS INC is GRTX and it is listed on the Nasdaq exchange.
On which exchange is GRTX stock listed?
GRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GALERA THERAPEUTICS INC stock?
7 analysts have analysed GRTX and the average price target is 0.38 USD. This implies a price increase of 163.79% is expected in the next year compared to the current price of 0.145. Check the GALERA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GALERA THERAPEUTICS INC worth?
GALERA THERAPEUTICS INC (GRTX) has a market capitalization of 7.89M USD. This makes GRTX a Nano Cap stock.
How many employees does GALERA THERAPEUTICS INC have?
GALERA THERAPEUTICS INC (GRTX) currently has 31 employees.
What are the support and resistance levels for GALERA THERAPEUTICS INC (GRTX) stock?
GALERA THERAPEUTICS INC (GRTX) has a resistance level at 0.19. Check the full technical report for a detailed analysis of GRTX support and resistance levels.
Should I buy GALERA THERAPEUTICS INC (GRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GRTX, evaluating the profitability, health, valuation and growth aspects
- GALERA THERAPEUTICS INC (GRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GALERA THERAPEUTICS INC (GRTX) Sales and EPS estimates to see what analysts future expectations are.
- GALERA THERAPEUTICS INC (GRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GALERA THERAPEUTICS INC (GRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- GALERA THERAPEUTICS INC (GRTX) Stock Chart to make your own analysis
- GALERA THERAPEUTICS INC (GRTX) Latest news and press-releases to stay up to date.
Does GALERA THERAPEUTICS INC (GRTX) stock pay dividends?
GRTX does not pay a dividend.
When does GALERA THERAPEUTICS INC (GRTX) report earnings?
GALERA THERAPEUTICS INC (GRTX) will report earnings on 2024-08-12, before the market open.
What is the Price/Earnings (PE) ratio of GALERA THERAPEUTICS INC (GRTX)?
GALERA THERAPEUTICS INC (GRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
What is the Short Interest ratio of GALERA THERAPEUTICS INC (GRTX) stock?
The outstanding short interest for GALERA THERAPEUTICS INC (GRTX) is 0.11% of its float. Check the ownership tab for more information on the GRTX short interest.
GRTX Technical Analysis
GRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GRTX. GRTX has a bad profitability rating. Also its financial health evaluation is rather negative.
GRTX Financial Highlights
Over the last trailing twelve months GRTX reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 55.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -232.8% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to GRTX. The Buy consensus is the average rating of analysts ratings from 7 analysts.